• Incyte will present new oncology data at the ESMO Congress in Madrid, October 23-27, 2026.
• Findings inform ongoing Phase 3 development of its KRAS G12D inhibitor and TGFβR2×PD-1 antibody, according to research chief Pablo J. Cagnoni.
• Upcoming presentations cover INCB161734 in advanced colorectal and pancreatic cancers, plus INCA33890 combinations in microsatellite-stable colorectal cancer.
• Another presentation will report preliminary efficacy of INCB123667 with bevacizumab in recurrent epithelial ovarian cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20261018477134) on October 18, 2026, and is solely responsible for the information contained therein.